Oppenheimer, a leading investment firm, has recently initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), highlighting the company’s robust pipeline in targeted radionuclide therapies (TRTs). With three TRTs currently in clinical development, Fusion Pharmaceuticals is poised to be a leader in the field.
Analysts Jeff Jones and Kyle Yang from Oppenheimer have given Fusion Pharmaceuticals an Outperform rating and set a price target of $13, indicating their confidence in the company’s potential.
Fusion Pharmaceuticals is making significant strides in the treatment of metastatic castration-resistant prostate cancer (mCRPC), a competitive and well-established field. Additionally, the company is exploring innovative targets for various solid tumors.
Also Read: Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst.
One of Fusion Pharmaceuticals’ key candidates is FPI-2265, an alpha-emitter that has the potential to compete directly against beta-emitters for mCRPC patients. If successful, it could provide more than double the upside to Oppenheimer’s current valuation. The interim Phase 2 data for FPI-2265 is expected to have a significant impact and is anticipated to be released in the first quarter of 2024.
Novartis AG (NYSE: NVS) recently faced supply challenges, underscoring the importance of a well-managed supply chain in meeting the growing demand for Targeted Radiation Therapies (TRTs). Fusion Pharmaceuticals, with its expertise in isotope supply and substantial investments in multiple suppliers, is well-positioned to maintain a strong market standing.
Price Action: As of the last check on Friday, Fusion Pharmaceuticals’ shares (FUSN) were down 8.71% at $2.41.